IDH2 and astrocytoma (excluding glioblastoma): This proposal stemmed from the finding of the immunohistochemical loss of H3K27me3 in 25/26 IDH-mutant and 1p/19q codeleted oligodendrogliomas and its retention in 120/135 astrocytomas [14].